Bala Subramanian, PhD, highlights how the novel antibiotic BWC0977, with its dual intravenous and oral formulation, is poised to transform the fight against antimicrobial resistance.
Bala Subramanian, PhD
Advertisement
COO and head of R&D at Bugworks
Articles by Bala Subramanian, PhD
Advertisement
Latest Updated Articles
Bugworks' Antibiotic BWC0977 Targets Resistant PathogensSeptember 6th 2024
Advertisement
Advertisement
Trending on Contagion Live
1
Bepirovirsen Phase 3 Results Offer Potential Cure for Chronic Hepatitis B
2
FDA Expands Merck Pneumococcal Vaccine Indication to Include At-Risk Children and Adolescents
3
Review of Cefepime and Zidebactam: A Novel Antibiotic Approved to Treat Complicated Urinary Tract Infections
4
FDA Approves Tebipenem Pivoxil as First Oral Carbapenem For Complicated Urinary Tract Infections
5